ZYME at a glance
Zymeworks Inc. (ZYME, SEC CIK 1937653) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Zymeworks Inc. (ZYME) reported revenue of $106.0 million (up 38.9% from FY2024) and a net loss of $81.1 million. Diluted EPS was -$1.08.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Zymeworks Inc. (ZYME) shares worth $420.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Platshon Scott on November 18, 2026 of 15,292 shares at $24.95 per share.
- In the last 90 days, ZYME insiders reported 0 open-market purchases ($0) and 5 open-market sales ($1.8M) on Form 4, a net sale of $1.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $106.0M
- +38.9% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$1.8M
- 13F holders
- 27 funds
- $420.8M · +0 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: biotechnology company developing multifunctional antibody-based therapeutics for cancer, inflammation, and autoimmune diseases
- New emphasis: commercial launch and milestone revenue focus on Ziihera (zanidatamab-hrii), approved in biliary tract cancer and pending broader regulatory approvals
- Strategic shift: royalty financing via $250M sale of 30% future Ziihera royalties to Royalty Pharma supporting capital and reducing risk
- Key metric: milestone payments received $69.9M in 2025 from partners; potential up to $440M near-term Ziihera milestones from Jazz and BeOne
- Noteworthy fact: use of a special purpose entity to securitize royalties linked to Jazz Collaboration Agreement with a $250M loan maturing in 2042
Risk Factors
- Regulatory risk: BIOSECURE Act may restrict U.S. government contracts to companies using equipment/services from certain Chinese biotech firms, affecting partnerships and operations
- Geopolitical risk: Early-stage clinical supplies sourced from China exposed to ongoing U.S.-China trade tensions and tariffs, risking supply chain disruptions
- Operational risk: Dependence on third-party manufacturers and collaborators; manufacturing difficulties could delay product supply for clinical trials or commercialization
- Competitive risk: Intense competition from better-resourced companies for asset acquisitions may force paying higher prices, reducing potential returns
- Financial risk: Historical losses with only zanidatamab generating royalties; no other product approvals or revenues as of December 31, 2025
Management Discussion & Analysis
- Revenue $106.0M in 2025, up $29.7M (39%) YoY driven by milestone payments from J&J, BeOne, GSK, Daiichi Sankyo, and BMS
- Operating expenses: R&D $137.0M (up 2% YoY), G&A $61.5M (flat YoY); R&D increased due to early-stage programs, zanidatamab R&D down 115% to $(1.8)M
- Best segment: Collaboration revenue milestone growth from multiple partners; worst segment: Zanidatamab R&D costs down $13.7M due to program transition to Jazz
- Cash $270.6M as of Dec 31, 2025; share repurchase $92.5M ($30M completed in 2025, $62.5M through Feb 2026); new $250M loan with Royalty Pharma in March 2026
- Outlook: 2026 focus on Phase 1 trials for ZW191 and ZW251; IND filings for multispecific antibodies on track; Jazz plans zanidatamab sBLA Q1 2026 and potential commercial launch H2 2026
AI summary of the ZYME 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $256.5M vs $27.6M, up $228.9M YoY, driven by $250.0M Jazz milestone
- Royalty and other revenue $4.9M vs $2.4M, while YUPELRI collaboration revenue contributed $1.5M
- R&D expense $36.1M vs $35.6M, SG&A $42.7M vs $14.1M, with no quarterly margin figures disclosed
- Cash $100.5M at September 30, operating cash flow nine-month outflow $101.7M vs $22.7M
- $14.0M Q3 share repurchases, $532.0M Theravance acquisition payment, $250.0M Jazz milestone received October 2026
- Outlook: cash plus Jazz milestone funding expected for at least twelve months, 2026 profitability anticipated but inconsistent quarterly profitability expected
Risk Factors
- New trade-compliance risk: BIOSECURE Act and DOJ Data Security Program could restrict Chinese suppliers and sensitive-data transfers
- Most material update: 10% global import surcharge and proposed 100% pharmaceutical tariff, threatening China-sourced clinical supplies
- Regulatory risk: FDA accelerated BTC approval for Ziihera remains contingent on confirmatory-trial benefit
- Operational risk: single YUPELRI API supplier, drug-product supplier and warehouse create concentrated supply exposure
- Financial risk: $100 million TRELEGY ELLIPTA milestone anticipated in Q1 2027, subject to conditions and unavailable development information
AI summary of the ZYME 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Second 2026 Share Repurchase Program announced, signaling continued capital return to shareholders
- Potential reduction in shares outstanding, supporting per-share metrics if repurchases are executed
Item 8.01: Other Events
- New $200.0 million share repurchase authorization through 2028
- Initial 2026 program completed after $125.0 million authorization
Item EX-99.1: Item EX-99.1
- $200 million repurchase authorization through 2028, with approximately $140 million currently expected to be deployed
- Program launch before year-end 2026, following completion of the initial $125 million authorization
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for the three months ended September 30, 2026
- Full financial details and management commentary contained in Exhibit 99.1, the attached press release
Item 7.01: Regulation FD Disclosure
- Zymeworks identifies SEC filings, press releases, investor websites, conferences and social media as potential sources of material information
- Investors should monitor these channels for updates on product candidates, corporate developments and other market-sensitive disclosures
Item EX-99.1: Item EX-99.1
- 3Q revenue $256.5M vs $27.6M, driven by $250.0M Ziihera approval milestone from Jazz
- 2026 guidance raised: revenue $337M-$351M and Adjusted EBITDA $176M-$190M
Item EX-99.3: Item EX-99.3
- Pro forma combined revenue $321.2M and net income $11.8M for nine months ended September 30, 2026
- Full-year 2025 pro forma revenue $213.4M, but net loss $43.7M after merger and financing adjustments
AI summaries of ZYME 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ZYME
Don't miss the next ZYME filing
- Alerts as it files. A push when ZYME files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ZYME, by share count.
- Ask anything. An AI agent that reads every ZYME filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Platshon Scott | Sell | Nov 18, 2026 | 15,292 | $24.95 |
| Platshon Scott | M | Nov 18, 2026 | 37,037 | - |
| Platshon Scott | M | Nov 18, 2026 | 37,037 | - |
| Moore Paul Andrew | M | Nov 13, 2026 | 25,000 | - |
| Moore Paul Andrew | Sell | Nov 13, 2026 | 7,374 | $26.09 |
| Moore Paul Andrew | Sell | Nov 13, 2026 | 25,000 | $26.04 |
| Moore Paul Andrew | M | Nov 13, 2026 | 25,000 | $5.82 |
| Moore Paul Andrew | Sell | Nov 13, 2026 | 7,367 | $26.14 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $76.3M | $106.0M |
| Operating Income | - | -$137.1M | -$92.5M |
| Net Income | -$118.7M | -$122.7M | -$81.1M |
| Op. Margin | - | -179.7% | -87.3% |
| Net Margin | - | -160.8% | -76.6% |
| Balance Sheet | |||
| Total Assets | $580.9M | $463.1M | $346.5M |
| Equity | - | $338.8M | $268.5M |
| ROE | - | -36.2% | -30.2% |
| Per Share | |||
| EPS | $-1.72 | $-1.62 | $-1.08 |
| Cash Flow | |||
| Operating CF | - | -$110.0M | -$33.0M |
| CapEx | $2.5M | $2.0M | $1.5M |
Source: XBRL data in Zymeworks Inc. (ZYME)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ZYME share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $420.8M |
| Q2 2026 | 27 | $385.2M |
| Q1 2026 | 27 | $396.1M |
| Q4 2025 | 25 | $405.3M |
| Q3 2025 | 27 | $306.5M |
| Q2 2025 | 25 | $223.5M |
| Q1 2025 | 24 | $139.5M |
| Q4 2024 | 19 | $95.6M |
- Morgan Stanley+1.01M (+45%)
- Goldman Sachs Group+483.6K (+103%)
- Citadel Advisors LLC+278.3K (+30%)
- Franklin Resources+93.3K (+122%)
- D.E. Shaw & Co+88.6K (+61%)
- Dimensional Fund Advisors−464.5K (-47%)
- Citigroup−114.3K (-87%)
- Vanguard Portfolio Management LLC−40.2K (-8%)
- BlackRock−38.3K (-1%)
- Raymond James Financial−15.2K (-9%)
- Millennium Management+400.1K
- Renaissance Technologies LLC+26.8K
- FMR LLC (Fidelity)−702.6K
- Principal Financial Group−85.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ZYME filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 23, 2026 | - | Analysis | - |
| 4 | Oct 9, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | May 15, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 15, 2026 | - | - | |
| 4 | Apr 10, 2026 | - | - | - |
| 4 | Apr 10, 2026 | - | - | - |
| 4 | Apr 7, 2026 | - | - | - |
| 8-K | Apr 1, 2026 | - | - | - |
| 8-K | Mar 2, 2026 | - | Analysis | - |
| 8-K | Mar 2, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ZYME SEC filings: frequently asked questions
Are ZYME insiders buying or selling?
In the last 90 days, Zymeworks Inc. (ZYME) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $1.8 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ZYME stock?
As of September 30, 2026, the largest Zymeworks Inc. (ZYME) holders among the 13F filers tracked by SignalX were BlackRock ($111.6 million), Morgan Stanley ($85.7 million), Vanguard Capital Management LLC ($41.3 million), Citadel Advisors LLC ($31.6 million), State Street Corp ($29.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ZYME's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Zymeworks Inc. (ZYME) reported revenue of $106.0 million (up 38.9% from FY2024) and a net loss of $81.1 million. Diluted EPS was -$1.08. The figures come from the XBRL data in the 10-K.
What are the main risks in ZYME's latest 10-K?
In the 10-K filed March 2, 2026, Zymeworks Inc. (ZYME) flagged: Regulatory risk: BIOSECURE Act may restrict U.S. government contracts to companies using equipment/services from certain Chinese biotech firms, affecting partnerships and operations. Geopolitical risk: Early-stage clinical supplies sourced from China exposed to ongoing U.S.-China trade tensions and tariffs, risking supply chain disruptions. (AI summary of the Risk Factors section.)
What did ZYME report in its latest 8-K?
Zymeworks Inc. (ZYME) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Second 2026 Share Repurchase Program announced, signaling continued capital return to shareholders.
What are the latest ZYME SEC filings?
Zymeworks Inc. (ZYME) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 18, 2026.
What is ZYME's SEC CIK number?
Zymeworks Inc. (ZYME)'s SEC Central Index Key (CIK) is 1937653. EDGAR lists every ZYME filing under that number.
Ask anything about ZYME
The research agent reads ZYME's filings, financials, insider trades and 13F holders, then answers with sources.